These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 23432415)

  • 1. Effect of repeated doses of netazepide, a gastrin receptor antagonist, omeprazole and placebo on 24 h gastric acidity and gastrin in healthy subjects.
    Boyce M; Warrington S
    Br J Clin Pharmacol; 2013 Nov; 76(5):680-8. PubMed ID: 23432415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Netazepide, a gastrin/CCK2 receptor antagonist, causes dose-dependent, persistent inhibition of the responses to pentagastrin in healthy subjects.
    Boyce M; Warrington S; Black J
    Br J Clin Pharmacol; 2013 Nov; 76(5):689-98. PubMed ID: 23432534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single oral doses of netazepide (YF476), a gastrin receptor antagonist, cause dose-dependent, sustained increases in gastric pH compared with placebo and ranitidine in healthy subjects.
    Boyce M; David O; Darwin K; Mitchell T; Johnston A; Warrington S
    Aliment Pharmacol Ther; 2012 Jul; 36(2):181-9. PubMed ID: 22607579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of netazepide, a gastrin/CCK2 receptor antagonist, on gastric acid secretion and rabeprazole-induced hypergastrinaemia in healthy subjects.
    Boyce M; Dowen S; Turnbull G; van den Berg F; Zhao CM; Chen D; Black J
    Br J Clin Pharmacol; 2015 May; 79(5):744-55. PubMed ID: 25335860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomised trial of the effect of a gastrin/CCK
    Boyce M; van den Berg F; Mitchell T; Darwin K; Warrington S
    Eur J Clin Pharmacol; 2017 Feb; 73(2):129-139. PubMed ID: 27796466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis.
    Moore AR; Boyce M; Steele IA; Campbell F; Varro A; Pritchard DM
    PLoS One; 2013; 8(10):e76462. PubMed ID: 24098507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized Controlled Trial of the Gastrin/CCK
    Abrams JA; Del Portillo A; Hills C; Compres G; Friedman RA; Cheng B; Poneros J; Lightdale CJ; De La Rue R; di Pietro M; Fitzgerald RC; Sepulveda A; Wang TC
    Cancer Prev Res (Phila); 2021 Jun; 14(6):675-682. PubMed ID: 33782049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects.
    Williams MP; Sercombe J; Hamilton MI; Pounder RE
    Aliment Pharmacol Ther; 1998 Nov; 12(11):1079-89. PubMed ID: 9845397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A.
    Fossmark R; Sørdal Ø; Jianu CS; Qvigstad G; Nordrum IS; Boyce M; Waldum HL
    Aliment Pharmacol Ther; 2012 Dec; 36(11-12):1067-75. PubMed ID: 23072686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mobilization of rat stomach ECL-cell histamine in response to short- or long-term treatment with omeprazole and/or YF 476 studied by gastric submucosal microdialysis in conscious rats.
    Konagaya T; Bernsand M; Norlén P; Håkanson R
    Br J Pharmacol; 2001 May; 133(1):37-42. PubMed ID: 11325792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The gastrin receptor antagonist netazepide (YF476) prevents oxyntic mucosal inflammation induced by Helicobacter pylori infection in Mongolian gerbils.
    Sørdal Ø; Waldum H; Nordrum IS; Boyce M; Bergh K; Munkvold B; Qvigstad G
    Helicobacter; 2013 Dec; 18(6):397-405. PubMed ID: 23865485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Skeletal effects of a gastrin receptor antagonist in H+/K+ATPase beta subunit KO mice.
    Aasarød KM; Ramezanzadehkoldeh M; Shabestari M; Mosti MP; Stunes AK; Reseland JE; Beisvag V; Eriksen EF; Sandvik AK; Erben RG; Schüler C; Boyce M; Skallerud BH; Syversen U; Fossmark R
    J Endocrinol; 2016 Aug; 230(2):251-62. PubMed ID: 27325243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Netazepide Inhibits Expression of Pappalysin 2 in Type 1 Gastric Neuroendocrine Tumors.
    Lloyd KA; Parsons BN; Burkitt MD; Moore AR; Papoutsopoulou S; Boyce M; Duckworth CA; Exarchou K; Howes N; Rainbow L; Fang Y; Oxvig C; Dodd S; Varro A; Hall N; Pritchard DM
    Cell Mol Gastroenterol Hepatol; 2020; 10(1):113-132. PubMed ID: 32004755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of 7-day therapy with different doses of the proton pump inhibitor lansoprazole on the intragastric pH in healthy human subjects.
    Harder H; Teyssen S; Stephan F; Pfützer R; Kiel G; Fuchs W; Singer MV
    Scand J Gastroenterol; 1999 Jun; 34(6):551-61. PubMed ID: 10440603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Netazepide, a gastrin/cholecystokinin-2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis.
    Boyce M; Moore AR; Sagatun L; Parsons BN; Varro A; Campbell F; Fossmark R; Waldum HL; Pritchard DM
    Br J Clin Pharmacol; 2017 Mar; 83(3):466-475. PubMed ID: 27704617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The type 2 CCK/gastrin receptor antagonist YF476 acutely prevents NSAID-induced gastric ulceration while increasing iNOS expression.
    Webb DL; Rudholm-Feldreich T; Gillberg L; Halim MA; Theodorsson E; Sanger GJ; Campbell CA; Boyce M; Näslund E; Hellström PM
    Naunyn Schmiedebergs Arch Pharmacol; 2013 Jan; 386(1):41-9. PubMed ID: 23179899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of acid inhibition by either oral high-dose ranitidine or omeprazole.
    Hurlimann S; Abbühl B; Inauen W; Halter F
    Aliment Pharmacol Ther; 1994 Apr; 8(2):193-201. PubMed ID: 8038351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Twenty-four-hour intragastric acidity and plasma gastrin during 3-month treatment with omeprazole in healthy subjects.
    Delchier JC; Benamouzig R; Stanescu L; Ropert A; Vallot T; Wirquin V; Roudot F; Lamarque D; Hamelin B
    Aliment Pharmacol Ther; 1997 Aug; 11(4):747-53. PubMed ID: 9305485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic inhibitory effects of gastrin and histamine receptor antagonists on Helicobacter-induced gastric cancer.
    Takaishi S; Cui G; Frederick DM; Carlson JE; Houghton J; Varro A; Dockray GJ; Ge Z; Whary MT; Rogers AB; Fox JG; Wang TC
    Gastroenterology; 2005 Jun; 128(7):1965-83. PubMed ID: 15940630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of single intravenously administered doses of omeprazole and ranitidine on intragastric pH and plasma gastrin concentration in nonfed ponies.
    Baker SJ; Gerring EL
    Am J Vet Res; 1993 Dec; 54(12):2068-74. PubMed ID: 8116940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.